Clinical Trials in Wahroonga, Australia
6 recruiting
Showing 1–20 of 22 trials
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled97 locationsNCT07225946
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled538 locationsNCT05485961
Recruiting
Phase 2
Working Out M0 Bipolar Androgen Therapy
Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group69 enrolled12 locationsNCT06594926
Recruiting
Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 3
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Prostate CancerCryotherapyProstate Cancer Recurrent+3 more
Clarity Pharmaceuticals Ltd220 enrolled28 locationsNCT06970847
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Phase 1
Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knee
Avidence Therapeutics15 enrolled1 locationNCT07338266
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled253 locationsNCT07028853
Recruiting
Phase 1
Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
Lumbosacral RadiculopathySciaticaSciatic Radiculopathy+3 more
Consano Bio24 enrolled3 locationsNCT07264270
Recruiting
Phase 1
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
PYC Therapeutics116 enrolled9 locationsNCT06714006
Recruiting
Not Applicable
Akyva First In Human
Underactive Bladder
Iota Biosciences, Inc15 enrolled2 locationsNCT06956209
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled100 locationsNCT04752722
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421
Recruiting
Phase 1
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology320 enrolled35 locationsNCT05785754
Recruiting
Phase 3
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Germ Cell Tumor
University of Sydney500 enrolled28 locationsNCT02582697
Recruiting
Not Applicable
Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
Chronic Pain
Saluda Medical Pty Ltd200 enrolled23 locationsNCT04662905